455 results on '"J. Ruf"'
Search Results
2. Enhancing environmental models with a new downscaling method for global radiation in complex terrain
3. Further Reading
4. Index
5. 7. Street People
6. 5. Holy Strangers
7. Notes
8. Bibliography
9. 3. The Pilgrim’s Progress
10. 6. Guides for the Perplexed
11. 4. The Ride of Passage
12. Title Page, Copyright, Dedication
13. 2. Commerce with the Ancients
14. 1. Love of Ruptures
15. Acknowledgments, Quote
16. Contents
17. FDG-PET zur Response Evaluation der CD19-CAR-T-Zell-Therapie
18. Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0
19. Improvements of a Branch Module for an Inductive Voltage Adder Based on Measurements and Circuit Simulations
20. Bone marrow impairment during early [Lu-177]PSMA-617-Radioligand Therapy: hematotoxicity or tumor progression?
21. Absorbed dose to metastases in Lu-177-PSMA-617 therapy
22. Comparison of Quantitative Tumor Volume Assessment on [Ga-68]PSMA-11 and [F-18]PSMA-1007 PET/CT as a Response Criterion of [Lu-177]PSMA Radioligand Therapy
23. Analyse der Zeitaktivitätskurven bei der Dosimetrie von Metastasen und Nieren in der Lu-177 PSMA Therapie
24. Gastrin-releasing peptide receptor antagonist [Ga-68]RM2 PET/CT for staging of pre-treated, metastasized breast cancer
25. On the Performance of the DVB-T System in Mobile Environments.
26. Rate-distortion performance for joint source and channel coding of images.
27. Bewildered Travel: The Sacred Quest for Confusion
28. A High Performance Fixed Rate Compression Scheme for Still Image Transmission.
29. The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis
30. PO-1411 Number of PSMA-PET positive lymph nodes affects outcome in node positive prostate cancer patients
31. PD-0818 Association between plasma hypoxia markers and tumor hypoxia in head-and-neck cancer patients
32. PD-0581 Offline-adaptive planning of mpMRI- and PSMA-PET- based dose escalation: results of a phase II trial
33. 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
34. Operational rate-distortion performance for joint source and channel coding of images.
35. Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis
36. Der SULpeak und die Tumor Lesion Glycolysis als Prognoseparameter in der FDG-PET/CT beim lokal fortgeschrittenen Lungenkarzinom
37. Frühe Änderung des PSA nach PSMA-Radioligandentherapie als Prädiktor für biochemische Response und Overall Survival
38. A concept of digital terrestrial television broadcasting.
39. PD-0817 IL-6 as surrogate marker for PET-detected tumor hypoxia dynamics in head-and-neck cancer patients
40. Einfluss der Kenntnisse über Bestrahlungsplanung und Primärdiagnostik auf die Beurteilungssicherheit in der Rezidivdiagnostik des NSCLC mittels PET/CT
41. Berechnung der Jahresfolgedosis basierend auf der effektiven Halbwertszeit für Patienten bei Therapien mit Lu-177-PSMA-617 und –DOTATATE
42. Ist das Verhältnis von prätherapeutisch bestimmten Tumorvolumen in der FDG- und PSMA-PET/CT prädiktiv für das serologische Therapieansprechen nach zwei Zyklen Lu-177 PSMA-Ligandentherapie?
43. First clinical application of the novel PSMA-11-derived hybrid molecule PSMA-914 for preoperative PET/CT imaging and fluorescence-guided surgery of prostate cancer
44. PSMA-PET- and mpMRI-guided focal radiation dose escalation in primary prostate cancer patients – a planned safety analysis of a two-armed prospective phase II trial (HypoFocal)
45. PO-1329 Longterm Biochemical Recurrence-Free Survival after PSMA-PET/CT–Based Salvage Radiotherapy
46. Lässt sich die Nierendosis bei multizyklischen Therapien mit Lu-177 markierten Liganden durch die Dosimetrie im 1. Therapiezyklus abschätzen?
47. Association between gastrin-releasing peptide receptor expression based on Ga-68-RM2-PET and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer
48. Zusammenhang zwischen der mittels Ga-68-PSMA-PET/CT bestimmten Ganzkörper-Tumorlast und dem PSA-Verlauf vor und nach Lu-177-PSMA-Radioligandentherapie
49. Korrelationen von Tumorlast im FDG-PET und Biomarkern im Blut beim malignen Melanom
50. Hämatotoxizität nach PSMA-RLT – hängt sie von der Response ab?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.